Research

Insurance Stopped Covering Wegovy? What Now

Creator: Elena Marsh, Health Writer
Published: 2026-09-22

Massachusetts counted about 112,000 fewer commercially insured people using weight-loss GLP-1s in early 2026 after major insurers dropped coverage. Here is why plans are cutting, what that does not mean, and what is still open.

Elena Marsh, Health Writer September 22, 2026 6 min read

A woman sits on a bench beside an allotment shed beside a watering can

The short version

On September 17, 2026, the Massachusetts Health Policy Commission reported that about 112,000 fewer commercially insured residents used a weight-loss GLP-1 in early 2026 than in 2025, a 52% drop, after major insurers ended coverage.
Most cuts target weight-loss-only prescriptions. The commission counted Ozempic and Mounjaro as diabetes drugs, and the state employees' plan says diabetes medicines remain covered.
Nationally, 19% of employers with 200 or more workers covered GLP-1s for weight loss in 2025 (KFF), and 13 state Medicaid programs covered them for obesity as of January 2026.
Some plans still review requests for other labeled uses such as sleep apnea, heart-risk reduction or MASH, and CVS Caremark returns Zepbound to its main commercial formularies on October 1, 2026.
Cost or insurance problems were the reason for 47.6% of first-year stops in a Cleveland Clinic sample of semaglutide and tirzepatide users, so a coverage change is worth planning with a prescriber before the last covered fill.
A compounded prescription is a separate, self-pay product prepared by a licensed pharmacy for one patient; a licensed provider decides whether it is appropriate and may decline.

If your insurance stopped covering Wegovy or Zepbound this year, the most likely reason is a plan decision about cost, not a judgment about you or the medicine. Many insurers and employers now exclude GLP-1 drugs prescribed only for weight loss, while still covering them for type 2 diabetes. Massachusetts just measured how fast that happened: in early 2026, about 112,000 fewer commercially insured residents used a weight-loss GLP-1 than in 2025, a drop of 52%.

A GLP-1 is a medicine that copies a gut hormone involved in appetite and blood sugar. Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are the best known.

Massachusetts GLP-1 coverage: what the state reported

As of September 22, 2026, the day this article was written, a detailed public count of the pullback comes from the Massachusetts Health Policy Commission, an independent state agency that tracks health spending. On September 17, 2026, its board previewed a GLP-1 chapter from the first annual report of its new drug-policy office, with the detail in its board presentation.

What it found:

About 216,000 commercially insured residents used a weight-loss GLP-1 in 2025, up from 3,300 in 2019.
In the first three months of 2026, 112,000 fewer did. That is a 52% decline.
Net spending on GLP-1s in the state's commercial market reached roughly a billion dollars in 2025, roughly three-quarters of it for weight loss.
Blue Cross Blue Shield of Massachusetts, Point32 and Mass General Brigham Health Plan ended weight-loss coverage for many members in 2026. The Group Insurance Commission, which insures state employees, and MassHealth, the state's Medicaid program, followed in July.

Two details keep those numbers honest. The commission sorted drugs by label: Wegovy, Zepbound and Saxenda counted as weight-loss drugs, Ozempic and Mounjaro as diabetes drugs. And the count covers commercially insured residents aged 12 to 64, so MassHealth members are not in it. The July cutoffs came after the quarter it measured.

Citing the companies' August 2026 earnings calls, the report also says self-pay now accounts for 35% of Novo Nordisk's Wegovy sales and 45% of Eli Lilly's Zepbound prescriptions. Paying yourself can mean a brand at a cash price or a compounded prescription, two different products that come up below.

Why insurance stopped covering Wegovy for so many people

Cost, plainly. Plans are weighing a medicine many people could benefit from, often for years, against premiums everyone pays. The commission's leaders put it the same way: real value to patients, weighed against affordability for the whole system.

Massachusetts fits a national pattern. In KFF's 2025 employer survey, published in Health Affairs, 19% of firms with 200 or more workers covered GLP-1s used mainly for weight loss. Among the biggest firms, those with 5,000 or more workers, 43% did, but the full survey found that two in three of those big covering firms said it had a significant effect on their drug spending.

Medicaid is moving the same way. KFF counted 13 state Medicaid programs covering GLP-1s for obesity as of January 2026, after California, New Hampshire, Pennsylvania and South Carolina ended coverage, and before MassHealth's July cutoff.

What it does not mean

It does not mean the medicines were found unsafe. The Massachusetts report is about spending and access, not safety.

It does not mean diabetes coverage ended. The state employees' plan says diabetes medicines such as Ozempic and Mounjaro remain covered after its change.

And it does not always mean every door is closed. Some plans still review requests when the medicine treats another condition on its label. The Group Insurance Commission's notice lists three, as of June 17, 2026: moderate-to-severe obstructive sleep apnea in adults with obesity; lowering the risk of serious heart and stroke events in adults with established heart disease and a BMI of 27 or more; and MASH, a fatty-liver disease, with moderate to advanced scarring. Coverage still depends on a doctor's request and the plan's review.

What to check if your coverage ended

Start with the notice. An exclusion means the plan no longer pays for that use. A formulary change means it swapped which brand it prefers (a formulary is the plan's list of covered drugs). A denial for missing paperwork is a third thing. The tirzepatide insurance guide walks through each, including prior authorization, the plan's pre-approval review.

Why did my insurance stop covering Zepbound? For some people it was a formulary change. As of September 22, 2026, the day this article was written, CVS Caremark, one of the largest pharmacy benefit managers (the companies that run drug benefits for plans), has announced that Zepbound returns to its most common commercial formularies as a preferred option on October 1, 2026, after being removed from those lists in 2025. That helps only if your plan still covers weight-loss GLP-1s, and plans can customize the list. If it will not pay for Zepbound at all, LillyDirect versus compounded tirzepatide compares two self-pay routes.

Medicare works differently. The Medicare GLP-1 Bridge began July 1, 2026 and runs through December 31, 2027, for eligible people with Part D drug coverage; the Medicare GLP-1 guide covers who qualifies.

If you are paying out of pocket now

In a Cleveland Clinic study of 288 randomly selected adults without diabetes who stopped injectable semaglutide or tirzepatide within their first year, 47.6% stopped because of cost or insurance problems, by far the most common reason given (Gasoyan et al., Obesity, 2025).

A gap matters for health as well as money. In a one-year follow-up of the STEP 1 trial, people who stopped semaglutide after 68 weeks, along with the trial's lifestyle program, regained about two-thirds of the weight they had lost (Wilding et al., Diabetes, Obesity and Metabolism, 2022). And in a survey published in July 2026, about half of the primary care doctors who answered at a Midwestern academic medical center said they felt uncomfortable helping patients manage their weight after a large statewide insurer ended coverage in 2025 (Oshman et al., Obesity Pillars, 2026). That is a reason to raise the change with a prescriber before the last covered fill.

The self-pay routes, briefly:

A brand at a cash price. The manufacturers sell some brands directly, and the government's TrumpRx site lists those offers; TrumpRx GLP-1 prices has the current numbers.
HSA or FSA money. A prescribed GLP-1 for a diagnosed condition can often be paid from these tax-advantaged accounts; the HSA guide covers the paperwork.
A compounded prescription. Promise's semaglutide and tirzepatide are dispensed as compounded medications, prepared by a licensed U.S. compounding pharmacy for one patient, which is different from an FDA-approved product: the formulations offered here are not FDA-approved. They are self-pay, and they are not a cheaper copy of Wegovy or Zepbound.

A licensed provider reviews every request, and not everyone qualifies. A provider may still prescribe a compounded formulation when it is medically appropriate; that decision is between you and your doctor.

What the prescribed route adds is accountability: a named provider who reads your history and can say no, a licensed pharmacy whose preparation is labeled and traceable, and someone to contact if something feels wrong. A vial bought online without a prescription has none of those.

What to watch next

The full Massachusetts report. The commission says more will be shared in its drug-policy office's first annual report, due this winter.

October 1. Zepbound returns to CVS Caremark's main commercial formularies, for plans that choose to cover weight-loss GLP-1s at all.

Condition-based rules. The state employees' list of qualifying conditions is dated and, in the plan's own words, subject to change, so it is worth rechecking before assuming a request would fail.

Open enrollment. Employers set their 2027 drug benefits this fall, and the benefits guide is where a change shows up first. In KFF's 2025 survey, only 1% of large employers without coverage said they were very likely to add it within a year.

Common questions

Why did my insurance stop covering Wegovy?

Usually because the plan stopped paying for GLP-1 drugs prescribed only for weight loss, a cost decision rather than a safety finding. In Massachusetts, Blue Cross Blue Shield, Point32 and Mass General Brigham Health Plan did this for many members in 2026, and the state employees' plan and MassHealth followed in July. The notice should say whether it is an exclusion, a formulary change or missing paperwork, and each has a different next step.

Why did my insurance stop covering Zepbound?

Either the plan excluded weight-loss GLP-1s altogether, or its drug list switched to a different preferred brand. CVS Caremark removed Zepbound from its main commercial formularies in 2025 and announced on May 28, 2026 that it returns as a preferred option on October 1, 2026. That helps only if the plan still covers weight-loss GLP-1s, and plans can customize the list, so the plan itself has the final answer.

Does losing weight-loss coverage affect Ozempic or Mounjaro for diabetes?

In the changes described here, no. Weight-loss exclusions are a separate decision from diabetes benefits. The Massachusetts Health Policy Commission counted Ozempic and Mounjaro as diabetes drugs in its analysis, and the state employees' plan says diabetes medicines remain covered after its July 2026 change. Plans differ, so the plan's own drug list and prior authorization rules for the diabetes use are what decide it.

Can I appeal if my plan dropped GLP-1 coverage for weight loss?

You can ask, but what an appeal can do depends on the reason for the denial. A written exclusion for weight-loss use is set by the plan's documents. If another labeled condition applies, such as moderate-to-severe sleep apnea, established heart disease or MASH, some plans review a request from the doctor under that condition. A denial for missing paperwork can often be fixed by resubmitting the right records.

Which Massachusetts health plans dropped GLP-1 coverage for weight loss?

The Massachusetts Health Policy Commission's September 17, 2026 release names Blue Cross Blue Shield of Massachusetts, Point32 and Mass General Brigham Health Plan, which discontinued weight-loss coverage for many members in 2026. The Group Insurance Commission, which covers state employees, and MassHealth also ended coverage of GLP-1s for weight loss beginning July 2026. Diabetes coverage is a separate benefit.

Does insurance cover compounded semaglutide?

Generally not; a compounded prescription is paid out of pocket. It is a separate product, prepared by a licensed compounding pharmacy for one patient, and not a discounted Wegovy. Through Promise, a licensed provider reviews the request, prescribes only when it is medically appropriate, and may decline. HSA or FSA funds can sometimes pay for a prescribed medicine that treats a diagnosed condition, subject to the administrator's rules.